Mark Liberman is a Trustee Professor at the University of Pennsylvania , holding appointments in the Department of Linguistics and Department of Computer and Information Science . He serves as Director of the Linguistic Data Consortium and Faculty Director of Ware College House . His career spans linguistics, speech technology, and computational methods. Education: Harvard University (1965-1969), MIT (M.S. 1972, Ph.D. 1975) Professional Experience: AT&T Bell Laboratories (1975-1990), University of Pennsylvania (1990-present) His research interests include: Corpus-based Phonetics : Analyzing speech patterns via large-scale datasets. Clinical Applications : Developing speech biomarkers for neurodegenerative diseases. Tonal Phonology : Studying lexical tone and intonation in languages like Yoruba and Mandarin. Formal Annotation Models : Creating frameworks for linguistic data standardization. Recent publications highlight automated speech analysis, cross-linguistic prosody, and digital biomarkers for conditions like ALS-FTD and Alzheimer’s. His collaborations span computational linguistics , neurology , and cognitive science . Scientific awards include the IEEE James L. Flanagan Award (2017), Antonio Zampolli Prize (2010), and fellowships from the AAAS and Linguistic Society of America . He advises PhD students May Chan and Jonathan Him Nok Lee and contributes to editorial boards for journals like Cognition and Annual Review of Linguistics . His work bridges speech science , language technology , and neurocognitive research .
Dr. Camila Aquino serves as Assistant Professor in both the Department of Clinical Neurosciences and Department of Community Health Sciences at the University of Calgary's Cumming School of Medicine, and is a Full Member of the Hotchkiss Brain Institute. As Medical Director of the Deep Brain Stimulation Program, she specializes in Parkinson's disease, essential tremor, dystonia, and chorea management, including EMG-guided botulinum toxin injections. Her educational background includes: M.D. in Medicine from Escola Superior de Ciencias da Santa Casa (2005) M.S. in Neurosciences from Federal University of Sao Paulo (2012) Ph.D. in Neurosciences from Federal University of Sao Paulo (2019) M.S. in Health Research Methods, Clinical Epidemiology from McMaster University (2020) Dr. Aquino's research addresses unmet needs in movement disorders through innovative clinical trial designs for Parkinson's disease, focusing on precision-medicine approaches, early intervention, and outcome optimization. She actively evaluates neuromodulation therapies including Deep Brain Stimulation, Spinal Cord Stimulation, and MRgFUS, with emphasis on expanding indications and improving patient outcomes. As an International Parkinson and Movement Disorder Society member, she chairs the web-based learning committee and serves on evidence-based medicine and outcome measure committees. Analysis of her 15 most recent publications (2021-2025) reveals a cohesive research trajectory centered on Parkinson's disease management, with dominant themes in motor fluctuation treatments, deep brain stimulation methodology, and clinical trial innovation. Her work bridges fundamental clinical practice guidelines with advanced neuromodulation technologies, demonstrating consistent commitment to evidence-based solutions for movement disorders. Her scientific recognition includes: Parkinson Canada research grant Mohammed Al Zaibak Foundation scholarship CAPES scholarship from Brazilian Ministry of Education Dr. Aquino has secured significant research funding supporting clinical trials in Parkinson's disease neuroprotection and neuromodulation therapies. While specific student advisees aren't listed, her leadership of the DBS Program and active clinical trial portfolio indicate substantial mentorship responsibilities. Her grant portfolio emphasizes translational research with direct clinical impact. She directs the University of Calgary's Deep Brain Stimulation Program and contributes to the MRI-guided focused ultrasound initiative. Through her International Parkinson and Movement Disorder Society committee roles, she shapes global educational standards and evidence-based practices in movement disorders.
Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.
Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .
Un J. Kang, MD is the Founders Professor of Neurology at NYU Grossman School of Medicine and Professor in the Department of Neuroscience and Physiology. He serves as Director of Translational Research at the Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders and Co-Director of the Parekh Center for Interdisciplinary Neurology. His clinical practice focuses on Parkinson's disease and related movement disorders including tremor, dystonia, and Huntington's disease. Dr. Kang earned his MD from Johns Hopkins University in 1982, completed residency in Neurology at NY Presbyterian - Columbia University Medical Center in 1986, and specialized in Movement Disorders through fellowship training at the same institution in 1987. His research investigates the pathogenesis of Parkinson's disease and mechanisms of therapy, with particular focus on basal ganglia circuit plasticity, neural adaptation to dopamine loss, and development of biomarkers for neurodegenerative disorders. He pioneered experimental gene therapy approaches for Parkinson's disease and now directs the Kang Lab where his team studies how brain circuitry is perturbed by dopamine loss and pharmacological treatment in mouse models. Dr. Kang's research portfolio includes multiple NIH-funded projects examining striatal cholinergic interneuron dysfunction, freezing of gait mechanisms, and biomarker development for Parkinson's disease. His laboratory has published extensively on Parkinson's disease mechanisms with 178 publications to date, including significant recent work on alpha-synuclein detection methods and striatal pathway alterations in Parkinsonian motor deficits. Before joining NYU Langone in 2019, Dr. Kang created and led a multidisciplinary research team at the University of Chicago for two decades and previously served as chief of the movement disorders division at Columbia University. He leads the BioFIND consortium as principal investigator, banking biospecimens for Parkinson's disease biomarker discovery.
Najim Dehak is an Associate Professor in the Department of Electrical and Computer Engineering at Johns Hopkins University, part of the Whiting School of Engineering. His research focuses on machine learning applied to speech processing, audio classification, and health applications. He is renowned for developing the I-vector representation for speaker recognition, introduced in 2008 during a workshop at Johns Hopkins’ Center for Language and Speech Processing. Prior to this role, he was a research scientist at MIT’s Computer Science and Artificial Intelligence Laboratory. Dehak holds a PhD from the School of Advanced Technology in Montreal (2009). He is a Senior Member of IEEE and contributes to the IEEE Speech and Language Technical Committee. His work bridges AI, healthcare, and signal processing, with notable contributions to neurodegenerative disease detection via speech and handwriting analysis. Research interests include adversarial attacks on speech systems, multimodal biomarker discovery, and robust speech processing across demographics. His lab’s tools, like the Hermespeech Recorder, enable scalable data collection for clinical and research applications. Education: PhD in Advanced Technology (2009), Montreal Affiliations: Johns Hopkins University, IEEE Labs/Teams: Center for Language and Speech Processing (CLSP) His recent work explores AI’s role in aging research, including Alzheimer’s and Parkinson’s disease detection through speech, eye tracking, and handwriting analysis. Ongoing projects address fairness in speaker verification and robustness against adversarial attacks in ASR systems.
Thibault Mayor is a Professor in the Department of Biochemistry and Molecular Biology and the Michael Smith Laboratories at the University of British Columbia (Vancouver). His research focuses on understanding how cells manage misfolded proteins, with implications for neurodegenerative diseases like Parkinson's and Alzheimer's. He holds academic affiliations with the Centre for High-Throughput Biology (CHiBi) and has been recognized with awards including the UBC Killam Teaching Award (2020). Education: BSc, University of Geneva, Switzerland (1997) PhD, University of Geneva & Max Planck Institute of Biochemistry, Germany (2001) Postdoctoral Fellow, California Institute of Technology (2002) Research Interests: Mayor's lab investigates protein homeostasis, ubiquitin-proteasome system dynamics, and the molecular mechanisms underlying protein aggregation in aging and disease. Projects include proteomic approaches to identify aggregation-prone proteins and develop microbial cell factories for protein production. Grants & Awards: CIHR Project Grant ($730K, 2018) Michael Smith Foundation Career Award (2012) UBC Killam Teaching Award (2020) Labs & Collaborations: The Mayor Lab is part of the Michael Smith Laboratories and collaborates with computational biologists like Jörg Gsponer. They maintain active partnerships in proteomics and systems biology, contributing to initiatives like the BC Proteomics Network.
Anirban Paul is an Associate Professor in the Department of Neuroscience and Experimental Therapeutics at Pennsylvania State University, affiliated with the Penn State Neuroscience Institute. His research focuses on cellular and molecular mechanisms of GABAergic inhibitory circuits, with particular emphasis on interneuron biology and its implications in neurological disorders. Dr. Paul's research spans multiple neuroscience domains, with primary focus on GABAergic inhibitory circuits and interneuron biology. His work investigates how specific neuron subtypes, particularly Chandelier cells and cortical interneurons, contribute to brain function and dysfunction. He has made significant contributions to understanding the role of these cells in schizophrenia, Alzheimer's disease, and other neurological conditions. His research integrates molecular, cellular, and systems-level approaches to uncover fundamental mechanisms of neural circuit assembly, plasticity, and function. Key areas include RNA regulation in neuronal development, transcriptomic subtypes of inhibitory neurons, and cell-type specific vulnerabilities in neurodegenerative diseases. His research portfolio demonstrates consistent productivity with publications spanning from 2003 to 2025, showing an evolving focus from basic molecular neuroscience to translational research in neurological disorders. Recent work emphasizes single-cell analysis techniques and the role of specific interneuron populations in disease mechanisms, particularly in schizophrenia and Alzheimer's disease. His publications appear in high-impact neuroscience journals including Neuron, BMC Biology, and Frontiers in Cellular Neuroscience. Dr. Paul has received the NARSAD Young Investigator Award (2018), recognizing his promising research in neuroscience. His scientific contributions have been supported by multiple competitive grants from prestigious organizations including the National Institute on Aging (NIA) and the Brain and Behavior Research Foundation. He serves as Principal Investigator on multiple active research projects, including two major grants from the National Institute on Aging focused on cell-type specific risk and resilience in Alzheimer's disease and aging (2021-2024 and 2024-2026), as well as previous projects from the Brain and Behavior Research Foundation investigating Chandelier cells in schizophrenia. His research program demonstrates sustained funding and scientific leadership in the field of interneuron biology and its clinical implications.
California Institute of Technology (Caltech)United States
Shasha Chong is an Assistant Professor of Chemistry at the California Institute of Technology and a Ronald and JoAnne Willens Scholar. She earned her B.S. from the University of Science & Technology of China (2008) and Ph.D. from Harvard University (2014). Her research bridges chemistry, physics, and biology to investigate the molecular mechanisms of cellular processes, focusing on intrinsically disordered regions (IDRs) in transcription proteins. Research Focus: IDRs in transcriptional regulation, cancer biology, liquid-liquid phase separation, and single-molecule imaging techniques. Grants & Awards: CCE Innovation Award (2024), ALSF Innovation Grant, Mallinckrodt Research Grant, Margaret E. Early Medical Research Trust Grant. Collaborations: Caltech-City of Hope Biomedical Research Initiative Grant (2025). Teaching: Co-instructor for courses like Biochemistry Laboratory (Ch 11) and Advanced Topics in Biochemistry (BMB/Bi/Ch 174). Labs & Teams: Leads the Chong Laboratory at Caltech, focusing on interdisciplinary approaches combining single-molecule imaging, genome editing, and bioinformatics.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
Mayo Clinic College of Medicine and ScienceUnited States
Clifton R. Haider, Ph.D., is a Professor of Biomedical Engineering at Mayo Clinic, holding primary appointments as a Consultant in the Department of Physiology & Biomedical Engineering and the Department of Pediatric and Adolescent Medicine. His research focuses on accelerating medical device development through a discovery platform integrating mathematical modeling, algorithmic design, and physiological sensor validation. This platform aims to identify predictive biomarkers for conditions like cardiovascular collapse, sleep disorders, and neurodegenerative diseases. Dr. Haider’s work emphasizes noninvasive, autonomous monitoring and real-time predictive algorithms, with a particular focus on pediatric care. Education: PhD, Physiology & Biomedical Engineering, Mayo Graduate School, Mayo Clinic College of Medicine Predoctoral Studies in Biomedical Engineering and Physiology, Mayo Graduate School BSc (Hons), Biomedical Engineering, University of Iowa Research Interests: Dr. Haider’s work bridges engineering and clinical practice, targeting unmet needs in pediatric and adult healthcare. His discovery platform combines statistical modeling, sensor design, and validation to streamline medical device prototyping. Key focus areas include: Accelerated medical device design Quantitative predictive biomarkers Remote pediatric monitoring Real-time algorithm development This platform seeks to predict treatment responses and identify patients requiring advanced care, enhancing clinical decision-making. Awards: Office of Naval Research Young Investigator Program (2014–present) Grants & Labs: His research is supported by interdisciplinary collaborations at Mayo Clinic, leveraging laboratory facilities for sensor validation and algorithm testing. While specific grant details are not listed, his work aligns with Mayo’s emphasis on translational biomedical engineering.
Professor Neil Telling is Research Director at Keele's School of Pharmacy and Bioengineering, specializing in biomedical nanophysics. His research develops magnetic nanostructures for medical applications and investigates biomineralized iron deposits in neurological tissue using advanced synchrotron techniques. Research pillars: Nanoscale magnetic materials for targeted therapies X-ray spectromicroscopy of biological tissues Iron speciation in neurodegenerative conditions He maintains extensive international collaborations and regularly conducts experiments at major synchrotron facilities including the Advanced Light Source and Diamond Light Source.
Akbal Gill is a Clinical Fellow in the Department of Neurology at Yale School of Medicine. Their work intersects with various clinical programs including the Yale Headache and Facial Pain Center, Yale Concussion Program, and Neurocritical Care initiatives. As a member of the Neurology faculty, they contribute to resident education pathways such as the Clinician Educator Distinction and Global Neurology Distinction. The Neurology department at Yale encompasses diverse research areas like neuroimmunology, neuromuscular medicine, and experimental neuroimaging, with Gill's role likely involving collaboration across these domains.
Thomas Perlmann is a Professor in Molecular Developmental Biology at the Karolinska Institutet , leading research at the Department of Cell and Molecular Biology and serving as Director of the Stockholm Branch of the Ludwig Institute for Cancer Research. He also holds the position of Secretary General of the Nobel Assembly and Nobel Committee for Physiology or Medicine since 2016. Ph.D. , Karolinska Institutet, 1991 M.Sc. , Stockholm University, 1987 Research Interests : The Perlmann lab investigates the specification and maintenance of dopamine neurons in the central nervous system, with a focus on transcriptional regulation , signaling pathways , and regenerative medicine applications for Parkinson’s disease and other neurodegenerative disorders. His work bridges developmental biology and neuroscience , emphasizing the role of transcription factors in neuronal identity and function. Recent Research Trends : Perlmann’s recent publications highlight the use of single-cell RNA sequencing to dissect dopamine neuron heterogeneity , epigenetic regulation during development, and transcriptomic changes in Parkinson’s disease models. His studies increasingly leverage multiomics and bioinformatics to map neuronal lineage trajectories and gene expression dynamics. Scientific Awards : Royal Medal by HM the King (2025) Nicholson Lecturer, Rockefeller University (2011) Göran Gustafsson Prize in Molecular Biology (1999) Eric K. Fernström Young Investigator Prize (1997) Advising & Collaborations : While no student names are explicitly listed, Perlmann collaborates extensively with researchers such as Malin Parmar , Agnete Kirkeby , and Per Svenningsson on projects related to neuronal development and cell therapy . His lab receives funding from institutions like the Ludwig Institute for Cancer Research . Labs & Teams : The Perlmann Lab at Karolinska Institutet includes researchers like Linda Gillberg , Laura Lahti , and Behzad Yaghmaeian Salmani , who work on mouse models , single-cell transcriptomics , and bioinformatics to study dopamine neuron biology.
Cristian Gómez Canela is a Full Professor in the Department of Analytical and Applied Chemistry at the School of Engineering, Ramon Llull University (IQS). He serves as Coordinator of the Master's Degree in Analytical Chemistry and is an active member of the Catalan Chemical Society (SCQ), representing SCQ in EuChems-EYCN. His academic journey includes a PhD in Chemistry from the University of Barcelona (2014), followed by postdoctoral research at IDAEA-CSIC and King's College University. Dr. Gómez Canela's research focuses on environmental analytical chemistry, particularly the optimization and validation of analytical methods based on liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) and high-resolution mass spectrometry (HRMS) for determining organic pollutants in environmental samples. His work extends to metabolomics applied to aquatic organisms and the analysis of neurotoxic compounds in water systems. His research fingerprint reveals strong expertise in zebrafish models (100%), neurotransmitter analysis (66%), Daphnia magna studies (64%), and neurotoxicity assessment (21%). His recent publications (2024-2025) demonstrate a clear trend toward environmental neurotoxicology, with emphasis on the effects of pharmaceuticals and industrial pollutants on aquatic organisms. His work integrates advanced analytical techniques with biological endpoints to assess environmental risks, particularly focusing on neurological and cardiovascular impacts. The research spans method development for pollutant detection, environmental monitoring, and mechanistic studies of neurotoxic effects. Dr. Gómez Canela leads multiple significant research projects including CHEMIPARK (2024-2027) on passive sampling methodologies for environmental pollutants, GESPA (2022-2025) as part of the Environmental Process Engineering and Simulation Group, and several projects on neuroactive compounds in water systems. He has an impressive research output with 91 scientific publications from 2011-2025 and an h-index of 27 with over 2,000 citations. As a dedicated educator, he contributes to multiple academic programs including the Master in Analytical Chemistry, Master in Pharmaceutical Chemistry, and undergraduate degrees in Chemistry and Chemical Engineering. His research group GESPA represents a multidisciplinary team combining chemical engineering, biotechnology, and chemical analysis to advance environmental sustainability through theoretical and experimental approaches.
